PharmaMar presented results of a Phase II trial of lurbinectedin as a single agent in the treatment of progressive Malignant Pleural Mesothelioma (MPM) in an oral session during the European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
The Phase II, multicenter, international, single-arm trial, which enrolled 42 patients with progressive MPM achieving its primary endpoint of Progression-Free Survival (PFS) at 12 weeks in 52.4% of patients. The trial was carried out by SAKK (Swiss Group for Clinical Cancer Research) in collaboration with PharmaMar.
About Malignant Mesothelioma
Malignant mesothelioma is a tumor that originates from the mesothelial cells of the pleural, peritoneal or pericardial lining, and is often associated with exposure to asbestos, usually with a very poor prognosis at the time of diagnosis, the pleural mesothelioma being the most frequent location. The goal of current cancer treatments (surgery, radiation therapy, and chemotherapy) is to reduce or eliminate symptoms, as well as to prolong progression-free survival (PFS) and/or overall survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years due to the long latency period between exposure to asbestos and the appearance of the tumor.
Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.